Phytopharm surges on weight-loss drug success
The extract is derived from the African Hoodia cactus, which the San bushmen of the Kalahari desert have been eating for thousands of years to stave off hunger during long hunting trips. The cactus contains a molecule that fools the brain into believing the stomach is full. The licence for the molecule, discovered by South African scientists, was sold in 1997 to Phytopharm, which teamed up with Unilever to conduct safety and efficacy studies and bring the weight-loss product to market.
The yet-to-be-named treatment is expected to be launched in 2008, after first-stage tests showed it is commercially viable to produce the extract. Phytopharm and Unilever are embarking on clinical trials in the second stage of the project to make sure it works on humans and is safe to use. At the same time, Unilever is running a separate agronomy programme to determine whether the cactus, which takes 50 years to reach maturity, can be grown commercially.
As part of the 2004 co-operation agreement between the two companies, Unilever committed to an initial payment of £6.5m for the first stage and has now committed a further £3.5m out of a total of up to £21m in payments to Phytopharm. In addition Phytopharm will receive an undisclosed royalty on sales of all products containing the extract.
Richard Dixey, the chief executive of Phytopharm, said: "Our partnership with Unilever provides a fully funded programme and we look forward to generating royalty income from our partner's globally recognised brands."
After the clinical trials, expected to take a year, Unilever will work on the branding and marketing of the product. The consumer giant pumps €1bn (£694m) into research and development each year, the bulk of which is spent on developing "look good, feel good" products such as antioxidants in tea and appetite suppressants.
In January, Phytopharm struck a deal to license its skin treatment for dogs to Schering-Plough's animal health unit, with expected annual sales of up to $40m (£23m). The news on both treatments has given a welcome boost to Phytopharm, which suffered a setback in November when its Alzheimer's drug failed to show benefits in tests. Phytopharm shares closed up 4p at 43p.
- 1 'Not suppost to cry': 9-year-old lists the worst things about being a boy
- 2 Lee Evans announces his retirement from comedy on The Jonathan Ross Show
- 3 Iggy Azalea responds to Eminem rape lyrics: 'I'm bored of old men threatening young women'
- 4 These grandmas smoking weed for the first time are wonderful
- 5 Pastafarian former porn star Asia Lemmon allowed to wear colander in driving licence photo
Duchess of Alba dead: Billionaire Spanish duchess who lived life by her own rules, dies at 88
New York snowstorm: Death toll rises to 10 as residents battle with further snowfall
These grandmas smoking weed for the first time are wonderful
Chelsea balcony collapse: Two people dead and six injured in London
Woman opens professional cuddling shop – gets 10,000 customers in first week
Rochester by-election: Ukip gains second MP as Tory defector Mark Reckless holds seat
'Muslims pre-date Columbus in discovering America,' says Turkish president Erdogan
Rochester by-election: Labour MP Emily Thornberry resigns after posting white van and England flags tweet
France 'blocks' Russian sailors from boarding a warship
Former Tory PM Sir John Major says 'we would not have an NHS without migrants'
Revealed: How the world gets rich – from privatising British public services
iJobs Money & Business
Voluntary Only - Expenses Reimbursed: Reach Volunteering: Age Concern Slough a...
Voluntary Only - Expenses Reimbursed: Reach Volunteering: Crossroads Care is s...
£20000 - £25000 per annum + OTE £35,000: SThree: We consistently strive to be ...
£50000 - £90000 per annum + benefits: Ampersand Consulting LLP: Markit EDM (CA...